United Therapeutics Co. (NASDAQ:UTHR) Position Trimmed by Skandinaviska Enskilda Banken AB publ
Skandinaviska Enskilda Banken AB publ lowered its stake in United Therapeutics Co. (NASDAQ:UTHR) by 24.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 22,378 shares of the biotechnology company’s stock after selling 7,400 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.05% of United Therapeutics worth $2,122,000 as of its most recent filing with the SEC.
Other large investors also recently made changes to their positions in the company. Victory Capital Management Inc. raised its position in shares of United Therapeutics by 3.0% during the fourth quarter. Victory Capital Management Inc. now owns 10,493 shares of the biotechnology company’s stock worth $924,000 after purchasing an additional 304 shares during the period. Nuveen Asset Management LLC raised its holdings in United Therapeutics by 19.2% during the 4th quarter. Nuveen Asset Management LLC now owns 521,312 shares of the biotechnology company’s stock worth $45,917,000 after buying an additional 83,815 shares during the period. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in shares of United Therapeutics in the first quarter worth about $1,274,000. Massachusetts Financial Services Co. MA boosted its stake in United Therapeutics by 17.8% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 30,277 shares of the biotechnology company’s stock worth $2,871,000 after purchasing an additional 4,565 shares during the period. Finally, Empirical Finance LLC grew its position in United Therapeutics by 18.1% during the 1st quarter. Empirical Finance LLC now owns 25,685 shares of the biotechnology company’s stock worth $2,436,000 after purchasing an additional 3,935 shares in the last quarter. Institutional investors own 98.11% of the company’s stock.
A number of brokerages recently commented on UTHR. Credit Suisse Group upped their target price on United Therapeutics from $129.00 to $145.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Jefferies Financial Group raised shares of United Therapeutics from a “hold” rating to a “buy” rating and raised their price objective for the stock from $115.00 to $123.00 in a report on Tuesday, March 10th. They noted that the move was a valuation call. Zacks Investment Research raised shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $128.00 target price on the stock in a research note on Sunday, May 3rd. BidaskClub upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, June 24th. Finally, Wedbush reiterated a “buy” rating and issued a $243.00 price objective on shares of United Therapeutics in a research note on Thursday, June 25th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. United Therapeutics has an average rating of “Buy” and an average price target of $137.00.
United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.43 by $0.69. The company had revenue of $356.30 million for the quarter, compared to analysts’ expectations of $343.68 million. United Therapeutics had a return on equity of 19.19% and a net margin of 36.59%. United Therapeutics’s quarterly revenue was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.58 earnings per share. As a group, analysts expect that United Therapeutics Co. will post 10.4 EPS for the current year.
In related news, CEO Martine A. Rothblatt sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $121.00, for a total value of $1,210,000.00. Following the transaction, the chief executive officer now owns 10,140 shares in the company, valued at $1,226,940. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Judy D. Olian sold 4,510 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $124.96, for a total value of $563,569.60. Following the completion of the sale, the director now directly owns 3,490 shares of the company’s stock, valued at $436,110.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 207,610 shares of company stock valued at $24,546,906. Company insiders own 10.90% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Featured Article: Understanding Compound Annual Growth Rate (CAGR)
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.